Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.21 USD
0.00 (0.00%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 41 - 60 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RGLS4326/ADPKD: First Cohort Dosed; Biomarker Data Anticipated in Early Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/FY20: Focus Remains on ADPKD Ph1b Data in Early Q2 to Address Clinical Hold
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/FY20: Focus Remains on ADPKD Ph1b Data in Early Q2 to Address Clinical Hold
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Regulus Therapeutics is a clinical-stage biotech company developing microRNA therapeutics.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Private Placement Extends Runway into Q4:21; Next, Clinical Hold Update in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Financials; RGLS4326/ADPKD Cohort 1 Ph1b Data Anticipated in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Ph1b ADPKD Study Underway; Sanofi Milestone Pays Down Debt
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
License and Loan Agreements Amended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Creative Restructuring Offsets Near-Term Debt Burden
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials; Next, RGLS54326/ADPKD Phase 1b To Start Later This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q20 Financial Reports Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Orphan Drug Designation Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RGLS4326/ADPKD Achieves Milestone with O.D.D.; Initial Ph1b Results YE:20/Q1:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RGLS4326/ADPKD: Ph1 MAD Completes Dosing; Next, Start Ph1b in H2:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Positive Safety Data in Healthy Volunteers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1; Topline Phase 1 RGLS4326/ADPKD MAD Results Anticipated in Mid:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
1Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R